There are two major mechanisms reported to prevent the autoreactivity of islet-specific CD8 ؉ T cells: ignorance and tolerance. When ignorance is operative, naïve autoreactive CD8 ؉ T cells ignore islet antigens and recirculate without causing damage, unless activated by an external stimulus. In the case of tolerance, CD8 ؉ T cells are deleted. Which factor(s) contributes to each particular outcome was previously unknown. Here, we demonstrate that the concentration of self antigen determines which mechanism operates. When ovalbumin (OVA) was expressed at a relatively low concentration in the pancreatic islets of transgenic mice, there was no detectable cross-presentation, and the CD8 ؉ T cell compartment remained ignorant of OVA. In mice expressing higher doses of OVA, cross-presentation was detectable and led to peripheral deletion of OVA-specific CD8 ؉ T cells. When crosspresentation was prevented by reconstituting the bone marrow compartment with cells incapable of presenting OVA, deletional tolerance was converted to ignorance. Thus, the immune system uses two strategies to avoid CD8 ؉ T cell-mediated autoimmunity: for high dose antigens, it deletes autoreactive T cells, whereas for lower dose antigens, it relies on ignorance.
T
he control of T cell-mediated autoimmunity has been extensively investigated in transgenic mice expressing model self antigens under the control of tissue-specific promoters. Particular effort has been invested into understanding the nature of T cell tolerance to pancreatic islet ␤ cell antigens, because of the prominent role of T cells in the pathogenicity of diabetes mellitus type I. In some of the first of these studies, viral proteins were expressed in pancreatic islets (1, 2) . Autoimmune diabetes did not occur in these mice, unless they were infected with the respective virus. These seminal studies demonstrated that CD8 ϩ T cells with specificity for model self antigens could be induced to become autoagressive by cross-reactive pathogen-associated antigens, but that under normal circumstances they ignored their specific self antigens. Transgenic autoantigens are, however, not always ignored. In particular, when ovalbumin (OVA)-specific CD8 ϩ T cells (OT-I) were injected into transgenic mice expressing membrane-bound OVA (mOVA) under the control of the rat insulin promoter (RIP-mOVA mice), which express mOVA in pancreatic islet ␤ cells and kidney proximal tubular cells, they were activated by a mechanism termed cross-presentation and responded to the autoantigen OVA by proliferating in the renal and pancreatic lymph nodes (LNs) (3) . This form of activation did not result in autoimmunity (unless unphysiologically high numbers of OT-I cells were transferred), but led to the deletion of OVA-specific T cells (4) . Likewise, tolerance rather than ignorance was observed in transgenic mice expressing simian virus 40 T antigen (5) or influenza virus hemagglutinin (6) . Hence, in the various transgenic models studied so far, both peripheral CD8 ϩ T cell tolerance and ignorance to islet antigens have been reported. What determined whether ignorance or tolerance prevailed was unknown.
Recently, we demonstrated that antigen dose is a major factor inf luencing whether OT-I cells are activated by crosspresentation. Using two lines of transgenic mice expressing different amounts of secreted OVA under the control of the rat insulin promoter, it was revealed that only the higher dose was effectively cross-presented. This was despite the fact that both doses were sufficient to target islet cells for destruction by activated cytotoxic T lymphocytes (CTL). In RIP-OVA lo mice, which expressed the lower concentration of secreted OVA in pancreatic islets, OVA-specific CD8 ϩ T cells were not activated by cross-presentation in the draining LNs (7) . By contrast, RIP-OVA hi mice, which express a higher concentration, were able to stimulate T cells by cross-presentation. Because deletion has been shown to be associated with cross-presentation of OVA (4), these findings suggested that OVA-specific T cells might be deleted in RIP-OVA hi mice but not in RIP-OVA lo mice. In this study, we prove this hypothesis, demonstrating a link between autoantigen dose and the deletion of autoreactive CD8 ϩ T cells.
Materials and Methods
Mice. All mice were bred and maintained at the Walter and Eliza Hall Institute for Medical Research (WEHI; Melbourne, Australia). Rag-1-deficient OT-I mice, RIP-mOVA mice, RIP-OVA hi mice, and RIP-OVA lo mice have been described previously (3, 7, 8) .
Fluorescent Labeling of OT-I Cells. 5,6-Carboxyfluorescein diacetate, succinimidyl ester (CFSE) labeling was performed as previously described (4, 9) . Briefly, Rag-1-deficient OT-I cells were resuspended in PBS containing 0.1% BSA (Sigma) at 10 7 cells per ml. For fluorescence labeling, 2 l of a CFSE (Molecular Probes) stock solution (5 mM in DMSO) was incubated with 10 7 cells for 10 min at 37°C. mice. The total number of OT-I cells was derived using the formula [(% V␣2 ϩ V␤5 ϩ cells in the CD8 on their bone marrow-derived cells, were generated by irradiating H-2 b RIP-mOVA mice with 900 cGy and injecting them with 5 ϫ 10 6 bm1 or C57BL͞6 (B6) T-depleted bone-marrow cells as described (3) . The next day, radioresistant T cells were depleted by i.p. injection of 100 l of T24 ascites f luid (anti-Thy-1). These mice were termed bm13RIP-mOVA mice and B63RIP-mOVA mice, respectively. OVA-Specific CTL Generation. OVA-specific CTL were generated as previously described (8) . Briefly, mice were primed with 10 g of OVA 257-264 peptide in complete Freund's adjuvant. After 7 days, spleens were removed and cultured with 10 8 1500-cGyirradiated OVA-loaded B6 spleen cells for 6 days. Cytotoxicity was assessed in a conventional 51 Cr-release assay using the H-2 b cell line EL4 and the OVA-expressing transfectant E.G7 as targets.
Quantitation of OVA Expression by Western Blot Analysis. Pancreata were collagenase-digested, and islets were separated by density gradient centrifugation (10) . Islets were handpicked under an inverted microscope and lysed in buffer containing 1% Triton X-100 and proteinase inhibitors (11) . The soluble fraction was recovered after centrifugation at 15,000 ϫ g. The total protein content was estimated by Lowry assay using BSA as the standard. Proteins were fractionated on SDS͞10% polyacrylamide gels and electroblotted onto nitrocellulose membranes. The membranes were incubated with rabbit anti-OVA serum at 1:100 (prepared in the Autoimmunity and Transplantation Division, WEHI) followed by swine anti-rabbit serum at 1:2000 (Dako), and immunoreactive proteins were detected with 125 I-labeled protein A. Purified OVA (Sigma) was included as a standard on all blots. Stained proteins were detected by using a PhosphorImager (Molecular Dynamics), and quantified by using IMAGE-QUANT software (Molecular Dynamics).
Results and Discussion
The Deletion of Autoreactive CD8 ؉ T Cells Induced by Cross-Presentation Is Restricted to High-Dose Self Antigens. We have previously shown that OVA-specific CD8 ϩ T cells (OT-I cells) adoptively transferred into RIP-mOVA mice, which express mOVA in pancreatic islet ␤ cells and kidney proximal tubular cells, were activated in LNs draining OVA-expressing tissues by a mechanism termed cross-presentation (3). This led to the deletion of OT-I cells, suggesting a role for cross-presentation in peripheral CD8 ϩ T cell tolerance (4). To investigate the role of antigen dose in this process, we generated several lines of transgenic mice expressing secreted OVA under the control of the rat insulin promoter. Two of these lines, RIP-OVA hi and RIP-OVA lo , were chosen for further analysis because of their clear differences in the level of OVA expression (7) . In earlier work, we provided evidence for different levels of antigen expression based on the fact that RIP-OVA hi but not RIP-OVA lo mice expressed sufficient antigen in pancreatic islets to be detected by immunohistology (7). We have now quantitated OVA expression by Western blotting of protein extracted from the islets. This revealed that RIP-OVA hi mice expressed 1.0 Ϯ 0.4 ng of OVA per g of protein in the pancreatic islets. In contrast, RIP-OVA lo mice expressed an undetectably low level of antigen that was Ͻ0.03 ng of OVA per g of protein, which is at least 33-fold less antigen than the high expressor. Both lines expressed physiologically relevant doses of OVA, as shown by the ability of in vitroactivated OT-I cells to recognize and destroy the islet ␤ cells of each line (7). They differed, however, in their ability to crosspresent OVA in the pancreatic draining LNs (Fig. 1, and see ref.  7 ). Like RIP-mOVA mice, RIP-OVA hi mice were able to cross-present OVA in the draining LNs of the pancreas, whereas RIP-OVA lo mice were unable to cause such CD8 ϩ T cell activation. Our analysis of the level of antigen expressed by islet cells in RIP-mOVA mice has been somewhat problematic because of mOVA running at a higher molecular weight (possibly due to multimerization), leading to its suboptimal transfer onto nitrocellulose. However, two separate preparations yielded expression averaging 2.2 ng per g of islet cell protein, which is very similar to the level of secreted OVA expressed in RIP-OVA (Fig. 3) . In this experiment, OT-I cells from RIP-OVA lo mice were able to proliferate in response to antigen, indicating that they had not been anergized. In contrast, LN cells from RIP-OVA hi mice, in which most OT-I cells had been deleted (Fig. 2) , showed a very weak OVA-specific proliferative response (Fig. 3) . To further support the idea that OT-I cells ignored OVA in RIP-OVA lo mice, we examined the expression of T cell activation markers after adoptive transfer of CFSE-labeled OT-I cells into both RIP-OVA lo mice and nontransgenic B6 mice. At 2 wk after transfer, there was no difference in the expression of CD44, CD62 ligand, and CD69 on OT-I cells in either recipient (data not shown).
Consistent with the lack of tolerance of transgenic OT-I cells transferred into RIP-OVA lo mice, the normal CD8 ϩ T cell repertoire of these mice was not tolerant to OVA, as indicated by their ability to generate an OVA-specific cytotoxic T cell response (Fig. 4) . Because only high-affinity CD8 T cells can lyse transfectants (12) , the ability of CTL from RIP-OVA lo mice to kill the E.G7 targets (EL4 transfectants expressing OVA) indicated that the CTL generated in these mice were not simply low-affinity T cells that remained after deletion of high-affinity clones. Thus, in the absence of cross-presentation, OVA-specific CD8 T cells ignored islet antigens and were fully responsive in vitro. This contrasts with what we observed for the normal CD8 T cell repertoire of RIP-mOVA mice. These mice express small amounts of OVA in the thymus, but when central deletion is prevented by thymectomy followed by bone marrow reconstitution and grafting of a normal B6 thymus graft, RIP-mOVA chimeras were still unable to generate OVA-specific CTL (Fig.  5) . This indicated that cross-presentation can tolerize a normal repertoire. Like RIP-mOVA mice, RIP-OVA hi mice also express OVA in the thymus, and we have yet to determine whether cross-presentation in this line leads to tolerance of their normal T cell repertoire. However, this outcome seems highly likely considering our findings with the RIP-mOVA chimeras.
Incapacitating Cross-Presentation Prevents Deletion. The above data suggested that cross-presentation was essential for deletion of OVA-specific CD8 T cells. If this was true, then deletion should be abolished in mice expressing high doses of OVA if crosspresentation is prevented. Such mice could be generated by introducing bone marrow of the bm1 haplotype (which cannot present OVA to OT-I cells) into RIP-mOVA mice of the B6 A RIP-OVA lo mouse or a nontransgenic littermate (A) was injected with OVA peptide in complete Freund's adjuvant. Then, 1 wk later, their spleens were removed and cultured in vitro with OVA-loaded spleen as previously described (8) . After 6 days, cultures were assayed for OVA-specific lytic activity by assessing their ability to lyse the OVA-transfectant E.G7 (s) or EL4 (ᮀ) cells.
background (bm13RIP-mOVA mice). This type of chimera is unable to cross-present OVA on its bone marrow-derived cells (3) but has the potential capacity to directly present OVA on parenchymal cells, such as the islet ␤ cells. In such bm13RIP-mOVA mice, deletion of OT-I cells was not evident, although it was detectable in control B63RIP-mOVA mice, which could cross-present OVA (Fig. 6 ). OT-I cells recovered from bm13RIP-mOVA mice proliferated in vitro when rechallenged with antigen, indicating that they had not been anergized (data not shown). Consequently, incapacitation of cross-presentation converted deletional tolerance into ignorance. Two apparently incompatible mechanisms have been reported to control CD8 ϩ T cell-mediated autoimmunity to islet antigens, i.e., tolerance (4-6) and ignorance (1, 2, 13) . This discrepancy is reflected by our transgenic mice expressing different concentrations of OVA. RIP-OVA hi mice showed deletional tolerance, whereas RIP-OVA lo mice, which express at least 33-fold less OVA, showed ignorance. We have recently demonstrated that only mice expressing relatively high doses of OVA are able to cross-present this protein (14) , and here we show that deletional tolerance was induced only in those mice that could cross-present OVA. This strongly implies that cross-tolerance depends on antigen dose. Consistent with this relationship between the presence of tolerance and the ability to cross-present a self antigen, we found that tolerance to hemagglutinin transgenically expressed in the pancreatic islets (6) also correlated with the ability to cross-present this molecule in the pancreatic draining LNs (15) . Furthermore, in mice expressing the MHC molecule H-2K b as a transgene in their islet cells, ignorance was seen (13) . Based on our findings, this is predictable because K b must be recognized as an entire MHC molecule and cannot be crosspresented to K b -specific CD8 ϩ T cells in the draining nodes. This latter point was reiterated in bm13RIP-mOVA mice, which could not cross-present OVA because their bone marrow compartment expressed an inappropriate class I MHC haplotype. Without cross-presentation, CD8 ϩ T cell deletion was abrogated, even when the antigen was expressed at a concentration known to be capable of cross-presentation.
Thus, our data provide direct evidence that different levels of expression of the same self antigen (in this case secreted OVA) can lead to completely different outcomes-deletional tolerance for high doses, and ignorance for low doses. Second, we provide direct correlation between cross-presentation and deletion, as we convert a deletional response in the RIP-mOVA mice to ignorance simply by preventing cross-presentation. It will be interesting to examine the relationship between antigen expression levels, cross-presentation, and peripheral CD8 ϩ T cell tolerance in the other transgenic models used in this field.
Although OT-I cells were not activated in the pancreatic LNs of RIP-OVA lo mice, it was possible that this antigen was cross-presented, but at a dose too low to activate OT-I cells. The lack of CD8 ϩ T cell tolerance in the normal repertoire of these mice suggested that there was no cross-presentation. It is possible, however, that the nature of tolerance in a normal T cell repertoire is more complex, with high-affinity͞avidity clones being deleted by cross-presented low-dose antigens, and loweraffinity͞avidity clones remaining ignorant. Consequently, for each antigen dose there would be a specific threshold affinity cut-off for deletion. This would also suggest that tolerance or ignorance observed in the transgenic systems studied so far would depend not only on antigen dose, but also on the affinity of the TCR transgene used.
In conclusion, our data provide an explanation for why some self antigens induce CD8 ϩ T cell tolerance, whereas others are ignored. That is, the dose of self antigen determines whether it will be cross-presented, and this in turn determines whether deletional tolerance will ensue. High-dose antigens are crosspresented and induce tolerance, whereas low-dose antigens are ignored. These findings reconcile a major discrepancy in the field of peripheral T cell tolerance.
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